Quick Answer
Apimeds Pharmaceuticals US, Inc. reported Stockholders Equity of -$1.36 million for fiscal year 2024.
Apimeds Pharmaceuticals US, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | -$1.36M | -4361.6% |
| 2023 | $31.9K | +104.5% |
| 2022 | -$713.6K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.16M | +879.8% | -16.2% |
| June 30, 2025 | $9.74M | +1463.9% | +653.1% |
| March 31, 2025 | -$1.76M | -565.3% | -29.6% |
| December 31, 2024 | -$1.36M | -4361.6% | -29.8% |
| September 30, 2024 | -$1.05M | — | -46.6% |
| June 30, 2024 | -$714.0K | — | -169.8% |
| March 31, 2024 | -$264.6K | — | -930.3% |
| December 31, 2023 | $31.9K | — | — |
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -4361.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2024 period, Apimeds Pharmaceuticals US, Inc.’s stockholders equity has declined by 90.3% (from -$713.6 thousand to -$1.36 million).
- The most recent figure is from Apimeds Pharmaceuticals US, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: